RYTM Rhythm Pharmaceuticals, Inc.
USHealthcareAs of 2026-10-09 12:20
Why RYTM matters now
Rhythm Pharmaceuticals, Inc. (RYTM) is a US stock in Healthcare. The latest InvestLog snapshot shows $91.91 with +2.53% on the session and $6.30B in market capitalization; recent performance reads 1-month +10.98% and YTD -9.58%.
The latest financial table shown here is Q1 2026, with revenue of $60.1M, net income of $-55.6M, and EPS of $-0.83. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1.8%.
The latest indexable market news headline is "Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law Firm" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $143.00; recent insider activity includes Smith Hunter C filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
53.53
P/S
30.57
EV/EBITDA
-37.64
DCF Value
$-381.41
FCF Yield
-1.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.4%
Operating Margin
-90.9%
Net Margin
-93.3%
ROE
-203.2%
ROA
-45.8%
ROIC
-56.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $60.1M | $-55.6M | $-0.83 |
| Q4 2025 | $57.3M | $-47.5M | $-0.73 |
| FY 2025 | $189.8M | $-196.5M | $-3.11 |
| Q3 2025 | $51.3M | $-52.9M | $-0.82 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$139.57
Target (Median)
$143.00
Target Range
$125.00 - $155.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.92
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.